Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer

Bruce E. Johnson, Pasi A. Jänne, Jeffrey Engelman, John Heymach, David Johnson, Glenwood Goss, Thomas Lynch

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Fingerprint Dive into the research topics of 'Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences